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http://dx.doi.org/10.1016/j.fjs.2012.Summary Small intestine tumors, such as gastrointestinal stromal tumors (GISTs), are rare
and difficult to be diagnosed. The most common GIST symptoms are abdominal pain and
bleeding. A novel enteroscopy method is helpful in the localization and preoperative evalua-
tion of small bowel tumors. We report a 77-year-old woman who had a history of leiomyoma
in the ileum 20 years previously. She presented with intermittent bloody stool passage. Path-
ological examination showed a GIST in the ileum measuring 3.5 cm  2.5 cm  2.0 cm. The aim
of this case report is to remind clinicians that GISTs should be considered if a patient with
a history of leiomyoma in the small bowel has obscure, inexplicable gastrointestinal bleeding.
Copyright ª 2012, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
In the past, leiomyoma was an unascertained diagnosis.
Since 1998, GISTwas diagnosed by Hirota et al, according to
mutations in the KIT gene.1 We now understand the
molecular pathogenesis of GISTs and use a specific targetastroenterology, Department
Hospital, Number 92, Section
Taiwan.
.org.tw (C.-W. Chang).
ight ª 2012, Taiwan Surgical Asso
09.003agent such as imatinib to block KIT and platelet-derived
growth factor receptor-alpha (PDGFR alpha).2,3 Imatinib is
indicated for treating unresectable or metastatic GISTs. We
report a patient who intermittently passed bloody stools,
which began years after she had had a complete resection
of a localized leiomyoma in the ileum.
2. Case report
A 77-year-old female had a history of leiomyoma in the
ileum. The tumor was approximately 6 cm  5.5 cm  5 cm.
It had caused intestinal obstruction and had beenciation. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 2 Single-balloon enteroscopy shows a submucosal
tumor with central deep ulceration (arrows).
24 W.-C. Lin et al.completely resected 20 years previously. She had been
intermittently passing bloody stools since 2 years before
her visit to our clinic. She had no recent fever, abdominal
pain, or weight loss. Esophagogastroduodenoscopy, colo-
noscopy, a small bowel barium study, and a red blood cell
(RBC) bleeding scan all failed to show the source of the
active bleeding. An abdominal computed tomography (CT)
study showed a soft tissue mass of approximately 3 cm in
the distal ileum (Fig. 1). Single-balloon enteroscopy for
preoperative marking revealed a submucosal tumor (Fig. 2)
in the distal ileum, approximately 20e25 cm from the
ileocecal valve. It measured approximately 3e4 cm and had
linear ulceration. At surgery, after enterolysis for small
bowel adhesion, a grayish friable tumor, measuring
3.5 cm  2.5 cm  2.0 cm, was found at the proximal ileum.
The tumor cells microscopically exhibited prominent
spindle cells in fascicles and in a focal storiform pattern
(Fig. 3). The mitotic rate was less than 1 per 50 high power
fields and the proliferation rate of Ki-67/MIB-1 was less
than 1%.The tumor cells were extensively immunoreactive
with CD117 and DOG-1; weakly immunoreactive with CD34;
and had a negative immunoreactivity for desmin. She was
diagnosed as having a GIST.3. Discussion
GISTs are the most common mesenchymal tumors of the
intestinal tract. They may occur anywhere in the wholeFigure 1 Abdominal computed scan shows a soft tissuemass of
approximately3 cm indistal ileumatantimesenteric site (arrow).gastrointestinal tract with 50e70% occurring in the
stomach; 25e30% in the small intestine; 5e10% in the
colonerectum; and less than 5% in the esophagus.2,4
Primary small intestine tumors are rare, and only 1e3% of
all gastrointestinal malignancies and GISTs are composed of
about 20% of these tumors.5 The infrequent location of the
small intestine and nonspecific symptoms of GISTs in the
small intestine may make diagnosis difficult. The rate of
detecting small intestine GISTs may be increased with the
development of new techniques such as capsule endoscopy
or balloon-assisted endoscopy.
Four percent to 53% of patients with a GIST are asymp-
tomatic and 19% of the patients are diagnosed incidentally.
The most common symptom of GISTs is abdominal pain
(38%) and the second most common symptom is bleeding
(30%).3 After the complete resection of the tumor, the
typical sites of tumor recurrence are the liver and perito-
neum. In a series by Dematteo et al,6 the median time to
recurrence was 1.5e2 years. The recurrence-free survival
at 1, 2, 5, and 10 years was 83%, 75%, 63%, and 60%,
respectively. The recurrence rate of GISTs was related to
the tumor location, size, and mitotic rate. For GISTs in the
small intestine, a large tumor size of 10 cm or greater and
a mitotic rate of more than 5 per 50 high power fields were
associated with a markedly high recurrence rate. The
leiomyoma in the ileum after resection proved to be
a predictor of recurrence in our patient.
Surgery and targeted molecular therapy are the two
gold standards for GISTs. Surgery is the first choice if
a complete resection is possible. Imatinib is indicated for
treating patients with KIT-positive (i.e., CD117-positive)
unresectable and/or metastatic GISTs. For KIT-mutant
proteins, imatinib is the choice drug and the response
rate is nearly 70%, even in advanced disease.3 In our
patient, the leiomyoma specimen obtained 20 years before
was not available and the recurrence rate in this type of
GIST would decrease as time progresses. Recurrent GIST in
our patient is thus an uncertified diagnosis. With prolonged
follow-up, it appears that almost all GISTs presenting with
Figure 3 (A) The tumor microscopically arises from the muscular layer of the intestinal wall extending to the mesentery
[hematoxylin and eosin (H&E) stain, 40%]. (B)The tumor cells exhibit prominent spindle cells in fascicles and focal storiform pattern
(H&E stain, 400%). (C) Immunohistochemistry stain shows that the tumor cells are extensively immunoreactive for c-kit (i.e.,
CD117). (D) Immunohistochemistry stain shows that the tumor cells are weakly immunoreactive for CD34.
Bleeding gastrointestinal stromal tumor 25clinical symptoms or signs leading to treatment have the
potential to behave in a malignant fashion.4 Based on
tumor size and mitotic count in a consensus approach to
GISTs, our GIST case appears to have a low risk of
malignancy.
The role of adjuvant treatment with imatinib after the
complete resection of primary GIST tumors is unknown. The
American College of Surgeons Oncology Group (ACOSOG)
Z9001 Trial7 showed that imatinib significantly reduces the
recurrence risk of a primary GIST that measures at least
3 cm (3% recurrence on imatinib vs. 17% without therapy at
12 months). We are inclined to think that the adjuvant
imatinib treatment should be prescribed for patients with
a tumor measuring 3.5 cm  2.5 cm  2.0 cm, although the
drug is not sponsored by the national health insurance in
Taiwan. Our patient preferred long-term follow-up rather
than taking medications.
In conclusion, enteroscopy is useful in preoperatively
evaluating small bowel tumors and obscure gastrointestinal
bleeding. If a patient with a long-term previous history
(e.g., 20 years) of leiomyoma in the ileum suffers from
obscure bleeding, we should consider a GIST. Imatinib
increases recurrence-free survival when administered soon
after the complete resection of a primary GIST.References
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